Investigating Metabolic, Brain, and Cognitive Alterations Through Bariatric Surgery
Opening soon NCT07704229
Run by Laval University · for 18 to 65 · All sexes
What this study is about
Despite global efforts, the prevalence of obesity continues to rise, with rates in Canada tripling over the past three decades. In addition to the well-established risk of cardiometabolic conditions such as heart disease and diabetes, obesity has been associated with cognitive decline and an increased risk of dementia later in life. Sleeve gastrectomy, the most widely used surgical treatment for severe obesity, has proven effective in promoting significant weight loss and improving overall health. Emerging research, including our recent brain imaging study, suggests that this surgery may also have a positive impact on brain health. Our findings demonstrated significant improvements, with patients experiencing reductions in brain age by 2.9 and 5.6 years 12 and 24 months post-surgery, respectively. Despite these promising results, the long-term effects of sleeve gastrectomy on brain health and cognitive function remains poorly understood. While some patients experience cognitive improvements following surgery, others do not, and the factors driving this variability remain unknown. This proposal aims to comprehensively investigate the impact of bariatric surgery on brain health by examining its cognitive consequences, determinants, and drivers. Understanding the key factors that contribute to brain health improvements after bariatric surgery is essential for optimizing its benefits, preventing relapse and developing personalized interventions to maintain or enhance brain health in individuals living with obesity.
Who can join (things the study team will check)
✅ You may be able to join if…
- Women or men between 18 and 65 years who meet the Guidelines for bariatric surgery (BM I≥ 30 kg/m2 with major comorbidities or BMI ≥ 35 kg/m2
🚫 You may not be able to join if…
- Pregnancy
- Liver cirrhosis
- Unstable medical, surgical or psychiatric conditions
- Substance or alcohol abuse
- Medications affecting the central nervous system
- Previous gastric, oesophageal, brain, or bariatric surgeries
- Gastrointestinal inflammatory diseases or ulcers
- MRI contraindications
Where this trial is running
- Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Quebec, Canada
Who to contact
Mélissa Pelletier, MSc · 418-656-8711 · melissa.pelletier@criucpq.ulaval.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07704229.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.